Reacción a "Phase 1 trial tests “weaponized” CAR-T cell therapy to improve lymphoma response"

The study is not particularly different from other phase 1 clinical trials, but it stands out for the striking efficacy results and for being the first clinical trial with successful results with new generation CAR-T therapy on an ultrafast platform.   

It is a phase 1 trial very limited in the number of cases, but with surprising results for the great efficacy of the therapy in patients who have relapsed to a CAR-T treatment. It is the first clinical study to be performed with fourth-generation CAR-T with successful results. In addition, toxicity is similar to that of second-generation CAR-Ts. 

The main limitation is that the data have to be confirmed in larger studies.